新型冠状病毒肺炎的当前治疗方法及输血相关技术的临床价值。
Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.
作者信息
Li Ying, Liu Shanglong, Zhang Shuchao, Ju Qiang, Zhang Shaoqiang, Yang Yuanming, Wang Haiyan
机构信息
Department of Blood Transfusion, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
出版信息
Transfus Apher Sci. 2020 Oct;59(5):102839. doi: 10.1016/j.transci.2020.102839. Epub 2020 Jun 3.
Abstract
COVID-19 is caused by SARS-CoV-2 which is a new enveloped virus that belongs to the Beta coronavirus genus. As a major health crisis, SARS-CoV-2 has infected over a million people around the world. There is currently no specific treatment available for patients with COVID-19 infection. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been used in clinical practice. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and discusses the clinical value of blood transfusion-related technologies used in COVID-19 treatment.
摘要
新型冠状病毒肺炎（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，SARS-CoV-2是一种新的包膜病毒，属于β冠状病毒属。作为一场重大的健康危机，SARS-CoV-2已感染了全球超过100万人。目前，对于新型冠状病毒肺炎感染患者尚无特效治疗方法。临床实践中已使用了多种潜在疗法，包括支持性干预、免疫调节药物、抗病毒治疗和恢复期血浆输注。在此，我们总结了目前针对新型冠状病毒肺炎感染相关疾病的潜在治疗方法，并讨论了新型冠状病毒肺炎治疗中使用的输血相关技术的临床价值。
相似文献
1
Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.
Transfus Apher Sci. 2020 Oct;59(5):102839. doi: 10.1016/j.transci.2020.102839. Epub 2020 Jun 3.
2
First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.
Transfus Apher Sci. 2020 Oct;59(5):102866. doi: 10.1016/j.transci.2020.102866. Epub 2020 Jul 1.
3
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
4
A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
Med Sci Monit. 2020 Dec 2;26:e928755. doi: 10.12659/MSM.928755.
5
Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.
Transfus Apher Sci. 2020 Oct;59(5):102820. doi: 10.1016/j.transci.2020.102820. Epub 2020 May 21.
6
Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.
Mayo Clin Proc. 2020 Dec;95(12):2801-2802. doi: 10.1016/j.mayocp.2020.09.033. Epub 2020 Oct 1.
7
Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan.
Transfus Apher Sci. 2020 Dec;59(6):102918. doi: 10.1016/j.transci.2020.102918. Epub 2020 Aug 27.
8
In Reply - Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients.
Mayo Clin Proc. 2020 Dec;95(12):2802-2803. doi: 10.1016/j.mayocp.2020.09.032. Epub 2020 Oct 1.
9
Anti-SARS-CoV-2 hyperimmune plasma workflow.
Transfus Apher Sci. 2020 Oct;59(5):102850. doi: 10.1016/j.transci.2020.102850. Epub 2020 Jun 10.
10
Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
Transfusion. 2021 Jun;61(6):1705-1709. doi: 10.1111/trf.16378. Epub 2021 Mar 22.
引用本文的文献
1
Correlation between bioactive lipids and novel coronavirus: constructive role of biolipids in curbing infectivity by enveloped viruses, centralizing on EPA and DHA.
Syst Microbiol Biomanuf. 2021;1(2):186-192. doi: 10.1007/s43393-020-00019-3. Epub 2021 Feb 3.
2
A study on blood donor characteristics and preferred environment of South Koreans during the COVID-19 pandemic: A conjoint analysis.
Front Public Health. 2023 Mar 15;11:1138430. doi: 10.3389/fpubh.2023.1138430. eCollection 2023.
3
Plasma exchange and COVID 19.
Transfus Apher Sci. 2022 Dec;61(6):103598. doi: 10.1016/j.transci.2022.103598. Epub 2022 Nov 12.
4
Functional food: complementary to fight against COVID-19.
Beni Suef Univ J Basic Appl Sci. 2022;11(1):33. doi: 10.1186/s43088-022-00217-z. Epub 2022 Mar 7.
5
COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies.
Transplant Proc. 2022 Jul-Aug;54(6):1504-1516. doi: 10.1016/j.transproceed.2021.12.014. Epub 2022 Jan 10.
6
The Impact of COVID-19 Pandemic on Blood Transfusion Services: A Perspective from Health Professionals and Donors.
J Multidiscip Healthc. 2021 Nov 2;14:3063-3071. doi: 10.2147/JMDH.S337039. eCollection 2021.
7
Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.
Pharmaceutics. 2021 Mar 5;13(3):342. doi: 10.3390/pharmaceutics13030342.
8
The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence.
J Clin Apher. 2021 Jun;36(3):483-491. doi: 10.1002/jca.21883. Epub 2021 Feb 12.
9
Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus 2) infection: case report and review.
Clinics (Sao Paulo). 2021 Jan 22;76:e2357. doi: 10.6061/clinics/2021/e2357.
10
Coronavirus disease (COVID-19) prevention and treatment methods and effective parameters: A systematic literature review.
Sustain Cities Soc. 2021 Jan;64:102568. doi: 10.1016/j.scs.2020.102568. Epub 2020 Oct 22.
本文引用的文献
1
Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4059-4061. doi: 10.26355/eurrev_202004_20976.
2
Using a diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus.
Int J Infect Dis. 2020 Jun;95:436-440. doi: 10.1016/j.ijid.2020.04.078. Epub 2020 May 1.
3
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.
Mol Cell. 2020 May 21;78(4):779-784.e5. doi: 10.1016/j.molcel.2020.04.022. Epub 2020 May 1.
4
Genomic Epidemiology of SARS-CoV-2 in Guangdong Province, China.
Cell. 2020 May 28;181(5):997-1003.e9. doi: 10.1016/j.cell.2020.04.023. Epub 2020 Apr 30.
5
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.
6
Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.
Aging Dis. 2020 Mar 9;11(2):216-228. doi: 10.14336/AD.2020.0228. eCollection 2020 Apr.
7
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
8
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
9
Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV.
J Med Virol. 2020 May;92(5):491-494. doi: 10.1002/jmv.25709. Epub 2020 Feb 21.
10
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
Zotero 插件